GU Cancers 2021 | SAPROCAN: saracatinib and docetaxel for mCRPC

Robert Jones, MD, PhD, University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, discusses the randomized Phase II SAPROCAN trial (ISRCTN22566729) of saracatinib (AZD0530), a Src kinase inhibitor, in combination with docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC). This study demonstrated that treatment with saracatinib and docetaxel did not improve outcomes in mCRPC and highlighted the importance of randomized Phase II trials evaluating combination therapies for prostate cancer. This interview took place during the 2021 Genitourinary Cancers Symposium.